Trump Medicaid Drug Pricing Plan
President Trump recently announced that all 50 states, plus the District of Columbia and Puerto Rico, would join a program designed to provide most favored nation pricing to certain prescription drugs for Medicaid recipients. According to Trump, the administration has made deals with pharmaceutical companies so that the cost of certain drugs would not be significantly higher than the prices paid in other nations.
We asked two professors and authors of Tax Facts with opposing political viewpoints to share their opinions about the Trump administration's newly announced deal to reduce the cost of prescription drugs in the Medicaid program.
Below is a summary of the debate that ensued between the two professors.
Their Votes:
Their Reasons:
Byrnes: For far too long, Americans have paid much higher prices for prescription drugs when compared with individuals in other developed countries. The Trump administration has now negotiated significant discounts on Medicaid drug pricing to bring prices in line with what drug companies are charging in those other countries—freeing up billions of dollars in the process.
Bloink: The Trump administration's actions on this front don't go nearly far enough to address the problem of rising health care costs in this country. Ordinary Americans are genuinely struggling to even pay for their health insurance premiums--largely because the GOP allowed the ACA enhanced premium subsidies to expire at the end of last year. We're talking about a small subset of prescription drugs and a reduction that is only available with respect to the Medicaid program. This is essentially the Trump administration grasping at straws before the midterm elections. It may be a good start—but we don't even know that because the terms of these deals with big pharma have not been released.
________________________________________
Byrnes: Trump's deal to lower Medicaid drug prices will save billions of dollars over the next decade--saving states that are now struggling to fund their Medicaid programs. States will be free to use those dollars to invest in healthcare improvements that are actually needed within their states. This system should allow states to provide relief from rising healthcare costs at the state level. It may not happen overnight, but in the end will be a much more effective solution.
Bloink: Medicaid is highly valuable and necessary to provide healthcare to the lowest-income Americans--but big picture, this is only a tiny sliver of relief. Trump's focus ignores the problems faced by the vast majority of middle and lower-income Americans—the rising cost of healthcare coupled with unchecked inflation. We have to address the root of the problem rather than focusing on one small piece of the pie.
________________________________________
Byrnes: Trump's savings on drug prices will essentially result in a system where the states are free to determine what they need, and will be free to use the extra funds to cover those needs, rather than the federal government stepping in and telling them what to do to help their people deal with the cost of healthcare. In the end, this approach will be much more effective than the failed one-size-fits-all ACA subsidy approach that was implemented at the federal level under the Biden administration.
Bloink: We also have to remember that drug companies that have agreed to these lower prices are only doing so in exchange for tariff relief and so that they can be exempt from providing similarly low prices to Medicare recipients. In the end, this program will have little impact--there's little evidence to suggest these drug companies will be providing any meaningful discounts at all. The parameters of the so-called deals have not even been made public—so currently, there's little to no evidence that this plan will have any impact at all.